# A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

> **NCT01114607** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** GSK1605786 ChemoCentryx: formulation A
- **DRUG:** GSK1605786 GSK: formulation B
- **DRUG:** GSK1605786 GSK direct-fill: formulation C
- **DRUG:** GSK1605786 GSK modified-process: formulation D
- **DRUG:** GSK1605786 GSK tablet: formulation E

## Key facts

- **NCT ID:** NCT01114607
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-05
- **Primary completion:** 2010-06-29
- **Final completion:** 2010-06-29
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01114607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01114607, "A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01114607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*